Kymera Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-311.4M | $-223.9M | $-147.0M | $-154.8M | $-100.2M | $-45.6M | $-41.2M |
| Depreciation & Amortization | $8.3M | $7.4M | $3.6M | $3.0M | $2.4M | $1.8M | $825.0K |
| Depreciation | $8.3M | $7.4M | $3.6M | $3.0M | $2.4M | $1.8M | $800.0K |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $59.9M | $55.0M | $43.1M | $35.5M | $25.0M | $5.2M | $1.2M |
| Net Cash from Operating Activities | $-232.9M | $-194.5M | $-102.8M | $-153.1M | $-128.9M | $88.1M | $17.9M |
| Investing Activities | |||||||
| Capital Expenditures | $1.4M | $12.8M | $34.5M | $2.8M | $1.6M | $9.1M | $532.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-521.1M | $-404.1M | $139.9M | $20.5M | $-99.8M | $-422.6M | $-16.5M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $990.7M | $608.9M | $4.2M | $153.0M | $250.3M | $289.3M | $34.9M |
| Net Change in Cash | $236.8M | $10.3M | $41.3M | $20.4M | $21.5M | $-45.2M | $36.3M |
| Free Cash Flow | $-234.3M | $-207.3M | $-137.3M | $-155.9M | $-130.5M | $79.0M | $17.4M |